secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2026-07-28T21:11:31+00:00
Accession:  0001104659-26-087601
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 2.01, 2.02, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Yarrow Bioscience completes reverse merger with VYNE; Yarrow stockholders own 97% of combined company
--------------------------------------------------------------------------------

- VYNE valued at $8.5M, Pre-Merger Yarrow at $272.9M; exchange ratio 0.7171 shares of new co per Yarrow share.
- Pre-Merger Yarrow stockholders own ~97% of combined company; VYNE stockholders ~3%.
- VYNE paid $17.3M cash dividend ($0.40242/share) to its stockholders prior to close.
- New board and officers appointed: CEO Rebecca Frey, CFO Tyler Zeronda, and four other C-suite; board of six members.
- Pre-Merger Yarrow raised $200M in total: $100M Series A preferred and $100M PIPE pre-closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/tm2620687d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-087601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer